#United States #Cambridge #Full Circles #genome engineering #cssDNA

Full Circles Therapeutics' Innovative Patent for Genome Modification

Full Circles Therapeutics, a pioneering name in the realm of genome engineering, has recently achieved a significant milestone by receiving a patent allowance from the United States Patent and Trademark Office (USPTO) for its foundational invention entitled "TARGETED GENOME MODIFICATION USING CIRCULAR SINGLE-STRANDED DNA." This advancement marks a turning point in genetic modification, promising to revolutionize methods and applications in biotechnology, gene therapy, and regenerative medicine.

The newly patented technology relies on circular single-stranded DNA (cssDNA) to facilitate focused, efficient gene modifications. This approach not only addresses vital challenges in genome engineering but also offers a promising alternative to traditional gene editing methods that frequently employ viral vectors or double-stranded DNA (dsDNA) donors. These conventional methods often come with disadvantages, including risk of immunogenic responses, cytotoxic effects, and potential off-target damage. In contrast, cssDNA provides a modular and scalable platform, enhancing gene integration efficiency while significantly minimizing these risks.

Advancing Genetic Innovation

The demand for accessible and safe genome editing solutions has soared in recent years, prompting scientists and researchers to seek alternatives to viral-based delivery systems, which can lead to unpredictable genomic integration and other complications. Full Circles Therapeutics addresses this need through its C4DNA™ GATALYST™ genome engineering platform. This innovative technology enables targeted transgene integration via homology-directed repair (HDR) without the associated risks tied to viral vectors. The result is a more precise method of genome modification with reduced toxicity—ideal for next-generation therapies, unobstructed by the challenges of viral methods.

Co-founder and Chairman Richard Shan emphasized the importance of this patent allowance, stating, "The allowance of this patent is a significant milestone in advancing non-viral genome editing. Our proprietary cssDNA platform offers a safer and more precise alternative for gene modification, paving the way for improved cell therapies and other transformative treatments."

Collaboration Opportunities

In a bid to catalyze innovation, Full Circles Therapeutics is actively pursuing licensing and partnership opportunities for its cssDNA platform with other enterprises in the biotech and pharmaceutical sectors. Co-founder and CSO Howard Wu expressed confidence in the potential applications of their technology, highlighting its relevance across various fields, including oncology, autoimmune disorders, and regenerative medicine. "By offering this platform for licensing, we aim to empower other innovators to enhance their gene editing capabilities and advance safer, faster, and more effective therapies," he noted.

As the landscape of genome engineering evolves, Full Circles Therapeutics continues to forefront this change, positioning its cssDNA-based technology as a leader in the industry. The company invites those interested in exploiting the capabilities of their groundbreaking platform to initiate discussions for licensing opportunities, thereby fostering advancements in the field of genetic modifications.

For media inquiries regarding licensing opportunities or further information about the technology, contact:

Flora Zhang
Director of Communications, Full Circles Therapeutics
Phone: (410) 733-0130
Email: contact@fullcirclestx.com

About Full Circles Therapeutics

Full Circles Therapeutics is at the forefront of biotechnology innovation, championing next-generation genome engineering solutions through its cssDNA platform. The company is driven by the mission to create safer, more efficient, and scalable genetic modifications that will transform cell and gene therapies, finally offering patients new hope and improved health outcomes. Visit www.fullcirclestx.com to learn more.